The global Chronic Granulomatous Disease (CGD) Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Chronic Granulomatous Disease (CGD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Granulomatous Disease (CGD) Treatment.

Report Scope

The Chronic Granulomatous Disease (CGD) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Granulomatous Disease (CGD) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Chronic Granulomatous Disease (CGD) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Chronic Granulomatous Disease (CGD) Treatment Market Report

Report Metric	Details
Report Name	Chronic Granulomatous Disease (CGD) Treatment Market
CAGR	5%
Segment by Type	X-Linked Chronic Granulomatous Disease Autosomal Recessive Chronic Granulomatous Disease
Segment by Application	Neutrophil Function Tests Genetic Testing Prenatal Testing
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc, Merck KGaA
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Granulomatous Disease (CGD) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Chronic Granulomatous Disease (CGD) Treatment Market report?

Ans: The main players in the Chronic Granulomatous Disease (CGD) Treatment Market are Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc, Merck KGaA

What are the Application segmentation covered in the Chronic Granulomatous Disease (CGD) Treatment Market report?

Ans: The Applications covered in the Chronic Granulomatous Disease (CGD) Treatment Market report are Neutrophil Function Tests, Genetic Testing, Prenatal Testing

What are the Type segmentation covered in the Chronic Granulomatous Disease (CGD) Treatment Market report?

Ans: The Types covered in the Chronic Granulomatous Disease (CGD) Treatment Market report are X-Linked Chronic Granulomatous Disease, Autosomal Recessive Chronic Granulomatous Disease

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 X-Linked Chronic Granulomatous Disease

1.2.3 Autosomal Recessive Chronic Granulomatous Disease

1.3 Market by Application

1.3.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Neutrophil Function Tests

1.3.3 Genetic Testing

1.3.4 Prenatal Testing

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Perspective (2019-2030)

2.2 Chronic Granulomatous Disease (CGD) Treatment Growth Trends by Region

2.2.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Chronic Granulomatous Disease (CGD) Treatment Historic Market Size by Region (2019-2024)

2.2.3 Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Region (2025-2030)

2.3 Chronic Granulomatous Disease (CGD) Treatment Market Dynamics

2.3.1 Chronic Granulomatous Disease (CGD) Treatment Industry Trends

2.3.2 Chronic Granulomatous Disease (CGD) Treatment Market Drivers

2.3.3 Chronic Granulomatous Disease (CGD) Treatment Market Challenges

2.3.4 Chronic Granulomatous Disease (CGD) Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Chronic Granulomatous Disease (CGD) Treatment Players by Revenue

3.1.1 Global Top Chronic Granulomatous Disease (CGD) Treatment Players by Revenue (2019-2024)

3.1.2 Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Players (2019-2024)

3.2 Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Chronic Granulomatous Disease (CGD) Treatment Revenue

3.4 Global Chronic Granulomatous Disease (CGD) Treatment Market Concentration Ratio

3.4.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Chronic Granulomatous Disease (CGD) Treatment Revenue in 2023

3.5 Chronic Granulomatous Disease (CGD) Treatment Key Players Head office and Area Served

3.6 Key Players Chronic Granulomatous Disease (CGD) Treatment Product Solution and Service

3.7 Date of Enter into Chronic Granulomatous Disease (CGD) Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Chronic Granulomatous Disease (CGD) Treatment Breakdown Data by Type

4.1 Global Chronic Granulomatous Disease (CGD) Treatment Historic Market Size by Type (2019-2024)

4.2 Global Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Type (2025-2030)

5 Chronic Granulomatous Disease (CGD) Treatment Breakdown Data by Application

5.1 Global Chronic Granulomatous Disease (CGD) Treatment Historic Market Size by Application (2019-2024)

5.2 Global Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Chronic Granulomatous Disease (CGD) Treatment Market Size (2019-2030)

6.2 North America Chronic Granulomatous Disease (CGD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024)

6.4 North America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size (2019-2030)

7.2 Europe Chronic Granulomatous Disease (CGD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024)

7.4 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size (2019-2030)

8.2 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2019-2024)

8.4 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size (2019-2030)

9.2 Latin America Chronic Granulomatous Disease (CGD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024)

9.4 Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size (2019-2030)

10.2 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024)

10.4 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Clinigen Group plc

11.1.1 Clinigen Group plc Company Detail

11.1.2 Clinigen Group plc Business Overview

11.1.3 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Introduction

11.1.4 Clinigen Group plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.1.5 Clinigen Group plc Recent Development

11.2 Orchard Therapeutics plc2032

11.2.1 Orchard Therapeutics plc2032 Company Detail

11.2.2 Orchard Therapeutics plc2032 Business Overview

11.2.3 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Introduction

11.2.4 Orchard Therapeutics plc2032 Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.2.5 Orchard Therapeutics plc2032 Recent Development

11.3 Horizon Therapeutics plc

11.3.1 Horizon Therapeutics plc Company Detail

11.3.2 Horizon Therapeutics plc Business Overview

11.3.3 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Introduction

11.3.4 Horizon Therapeutics plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.3.5 Horizon Therapeutics plc Recent Development

11.4 ViroMed. Co. Ltd

11.4.1 ViroMed. Co. Ltd Company Detail

11.4.2 ViroMed. Co. Ltd Business Overview

11.4.3 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Introduction

11.4.4 ViroMed. Co. Ltd Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.4.5 ViroMed. Co. Ltd Recent Development

11.5 Bellicum Pharmaceuticals, Inc

11.5.1 Bellicum Pharmaceuticals, Inc Company Detail

11.5.2 Bellicum Pharmaceuticals, Inc Business Overview

11.5.3 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Introduction

11.5.4 Bellicum Pharmaceuticals, Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.5.5 Bellicum Pharmaceuticals, Inc Recent Development

11.6 Pfizer Inc

11.6.1 Pfizer Inc Company Detail

11.6.2 Pfizer Inc Business Overview

11.6.3 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Introduction

11.6.4 Pfizer Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.6.5 Pfizer Inc Recent Development

11.7 Hoffmann-La Roche Ltd

11.7.1 Hoffmann-La Roche Ltd Company Detail

11.7.2 Hoffmann-La Roche Ltd Business Overview

11.7.3 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Introduction

11.7.4 Hoffmann-La Roche Ltd Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.7.5 Hoffmann-La Roche Ltd Recent Development

11.8 Novartis AG

11.8.1 Novartis AG Company Detail

11.8.2 Novartis AG Business Overview

11.8.3 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Introduction

11.8.4 Novartis AG Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.8.5 Novartis AG Recent Development

11.9 Lonza

11.9.1 Lonza Company Detail

11.9.2 Lonza Business Overview

11.9.3 Lonza Chronic Granulomatous Disease (CGD) Treatment Introduction

11.9.4 Lonza Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.9.5 Lonza Recent Development

11.10 GlaxoSmithKline plc

11.10.1 GlaxoSmithKline plc Company Detail

11.10.2 GlaxoSmithKline plc Business Overview

11.10.3 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Introduction

11.10.4 GlaxoSmithKline plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.10.5 GlaxoSmithKline plc Recent Development

11.11 Eli Lilly and Company

11.11.1 Eli Lilly and Company Company Detail

11.11.2 Eli Lilly and Company Business Overview

11.11.3 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Introduction

11.11.4 Eli Lilly and Company Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.11.5 Eli Lilly and Company Recent Development

11.12 Johnson & Johnson Services, Inc

11.12.1 Johnson & Johnson Services, Inc Company Detail

11.12.2 Johnson & Johnson Services, Inc Business Overview

11.12.3 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Introduction

11.12.4 Johnson & Johnson Services, Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.12.5 Johnson & Johnson Services, Inc Recent Development

11.13 Merck KGaA

11.13.1 Merck KGaA Company Detail

11.13.2 Merck KGaA Business Overview

11.13.3 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Introduction

11.13.4 Merck KGaA Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

11.13.5 Merck KGaA Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Clinigen Group PLC

Orchard Therapeutics plc2032

Horizon Therapeutics plc

ViroMed

Bellicum Pharmaceuticals Inc

Pfizer Inc

Hoffmann-La Roche Ltd

Novartis

Lonza

GlaxoSmithKline PLC

Eli Lilly and Company

Johnson & Johnson Services Inc.

Merck KGaA

List of Tables

Table 1. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of X-Linked Chronic Granulomatous Disease

Table 3. Key Players of Autosomal Recessive Chronic Granulomatous Disease

Table 4. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Region (2019-2024)

Table 8. Global Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Region (2025-2030)

Table 10. Chronic Granulomatous Disease (CGD) Treatment Market Trends

Table 11. Chronic Granulomatous Disease (CGD) Treatment Market Drivers

Table 12. Chronic Granulomatous Disease (CGD) Treatment Market Challenges

Table 13. Chronic Granulomatous Disease (CGD) Treatment Market Restraints

Table 14. Global Chronic Granulomatous Disease (CGD) Treatment Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Players (2019-2024)

Table 16. Global Top Chronic Granulomatous Disease (CGD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Treatment as of 2023)

Table 17. Ranking of Global Top Chronic Granulomatous Disease (CGD) Treatment Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Chronic Granulomatous Disease (CGD) Treatment Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Chronic Granulomatous Disease (CGD) Treatment Product Solution and Service

Table 21. Date of Enter into Chronic Granulomatous Disease (CGD) Treatment Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Type (2019-2024)

Table 25. Global Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Type (2025-2030)

Table 27. Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Application (2019-2024)

Table 29. Global Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Application (2025-2030)

Table 31. North America Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 46. Clinigen Group plc Company Detail

Table 47. Clinigen Group plc Business Overview

Table 48. Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Product

Table 49. Clinigen Group plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 50. Clinigen Group plc Recent Development

Table 51. Orchard Therapeutics plc2032 Company Detail

Table 52. Orchard Therapeutics plc2032 Business Overview

Table 53. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Product

Table 54. Orchard Therapeutics plc2032 Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 55. Orchard Therapeutics plc2032 Recent Development

Table 56. Horizon Therapeutics plc Company Detail

Table 57. Horizon Therapeutics plc Business Overview

Table 58. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Product

Table 59. Horizon Therapeutics plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 60. Horizon Therapeutics plc Recent Development

Table 61. ViroMed. Co. Ltd Company Detail

Table 62. ViroMed. Co. Ltd Business Overview

Table 63. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Product

Table 64. ViroMed. Co. Ltd Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 65. ViroMed. Co. Ltd Recent Development

Table 66. Bellicum Pharmaceuticals, Inc Company Detail

Table 67. Bellicum Pharmaceuticals, Inc Business Overview

Table 68. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Product

Table 69. Bellicum Pharmaceuticals, Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 70. Bellicum Pharmaceuticals, Inc Recent Development

Table 71. Pfizer Inc Company Detail

Table 72. Pfizer Inc Business Overview

Table 73. Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Product

Table 74. Pfizer Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 75. Pfizer Inc Recent Development

Table 76. Hoffmann-La Roche Ltd Company Detail

Table 77. Hoffmann-La Roche Ltd Business Overview

Table 78. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Product

Table 79. Hoffmann-La Roche Ltd Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 80. Hoffmann-La Roche Ltd Recent Development

Table 81. Novartis AG Company Detail

Table 82. Novartis AG Business Overview

Table 83. Novartis AG Chronic Granulomatous Disease (CGD) Treatment Product

Table 84. Novartis AG Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 85. Novartis AG Recent Development

Table 86. Lonza Company Detail

Table 87. Lonza Business Overview

Table 88. Lonza Chronic Granulomatous Disease (CGD) Treatment Product

Table 89. Lonza Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 90. Lonza Recent Development

Table 91. GlaxoSmithKline plc Company Detail

Table 92. GlaxoSmithKline plc Business Overview

Table 93. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Product

Table 94. GlaxoSmithKline plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 95. GlaxoSmithKline plc Recent Development

Table 96. Eli Lilly and Company Company Detail

Table 97. Eli Lilly and Company Business Overview

Table 98. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Product

Table 99. Eli Lilly and Company Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 100. Eli Lilly and Company Recent Development

Table 101. Johnson & Johnson Services, Inc Company Detail

Table 102. Johnson & Johnson Services, Inc Business Overview

Table 103. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Product

Table 104. Johnson & Johnson Services, Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 105. Johnson & Johnson Services, Inc Recent Development

Table 106. Merck KGaA Company Detail

Table 107. Merck KGaA Business Overview

Table 108. Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Product

Table 109. Merck KGaA Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)

Table 110. Merck KGaA Recent Development

Table 111. Research Programs/Design for This Report

Table 112. Key Data Information from Secondary Sources

Table 113. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Type: 2023 VS 2030

Figure 3. X-Linked Chronic Granulomatous Disease Features

Figure 4. Autosomal Recessive Chronic Granulomatous Disease Features

Figure 5. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Application: 2023 VS 2030

Figure 7. Neutrophil Function Tests Case Studies

Figure 8. Genetic Testing Case Studies

Figure 9. Prenatal Testing Case Studies

Figure 10. Chronic Granulomatous Disease (CGD) Treatment Report Years Considered

Figure 11. Global Chronic Granulomatous Disease (CGD) Treatment Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global Chronic Granulomatous Disease (CGD) Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Region: 2023 VS 2030

Figure 14. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Players in 2023

Figure 15. Global Top Chronic Granulomatous Disease (CGD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Treatment as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by Chronic Granulomatous Disease (CGD) Treatment Revenue in 2023

Figure 17. North America Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America Chronic Granulomatous Disease (CGD) Treatment Market Share by Country (2019-2030)

Figure 19. United States Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Canada Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Chronic Granulomatous Disease (CGD) Treatment Market Share by Country (2019-2030)

Figure 23. Germany Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. France Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. U.K. Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Italy Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Russia Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Nordic Countries Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Share by Region (2019-2030)

Figure 31. China Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Japan Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. South Korea Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. India Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Australia Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Chronic Granulomatous Disease (CGD) Treatment Market Share by Country (2019-2030)

Figure 39. Mexico Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Brazil Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Share by Country (2019-2030)

Figure 43. Turkey Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Saudi Arabia Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Clinigen Group plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 46. Orchard Therapeutics plc2032 Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 47. Horizon Therapeutics plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 48. ViroMed. Co. Ltd Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 49. Bellicum Pharmaceuticals, Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 50. Pfizer Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 51. Hoffmann-La Roche Ltd Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 52. Novartis AG Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 53. Lonza Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 54. GlaxoSmithKline plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 55. Eli Lilly and Company Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 56. Johnson & Johnson Services, Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 57. Merck KGaA Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Scar Silicone Gels Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-12F15742

Wed Aug 21 00:00:00 UTC 2024

Add to Cart

Global Varicose Vein Closure System Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-1R18103

Mon Aug 19 00:00:00 UTC 2024

Add to Cart

Global Moderate to Severe Atopic Dermatitis Treatment Drugs Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-7H18248

Fri Aug 16 00:00:00 UTC 2024

Add to Cart

Global Cellulitis Treatment Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-38X14265

Wed Aug 14 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions